Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Sold by SummitTX Capital L.P.

SummitTX Capital L.P. lowered its stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 37.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 206,847 shares of the company’s stock after selling 125,861 shares during the quarter. SummitTX Capital L.P. owned approximately 0.14% of Centessa Pharmaceuticals worth $8,216,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Virtus Investment Advisers LLC lifted its stake in Centessa Pharmaceuticals by 6.2% in the fourth quarter. Virtus Investment Advisers LLC now owns 10,034 shares of the company’s stock valued at $251,000 after buying an additional 583 shares during the last quarter. Coastal Bridge Advisors LLC grew its position in shares of Centessa Pharmaceuticals by 7.1% during the fourth quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company’s stock worth $351,000 after acquiring an additional 931 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Centessa Pharmaceuticals by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after acquiring an additional 979 shares during the period. TD Waterhouse Canada Inc. acquired a new stake in shares of Centessa Pharmaceuticals in the 4th quarter worth about $25,000. Finally, Wells Fargo & Company MN lifted its position in Centessa Pharmaceuticals by 42.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after purchasing an additional 1,008 shares during the last quarter. 82.01% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Leerink Partners cut shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and upped their target price for the stock from $36.00 to $40.00 in a research report on Wednesday, April 1st. Guggenheim cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 2nd. Needham & Company LLC downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Stephens lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Finally, Wolfe Research cut Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday, March 31st. Four investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $41.33.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA opened at $40.50 on Monday. The stock has a market cap of $6.27 billion, a price-to-earnings ratio of -22.63 and a beta of 1.11. The company has a debt-to-equity ratio of 0.23, a current ratio of 9.53 and a quick ratio of 9.53. Centessa Pharmaceuticals PLC Sponsored ADR has a 12 month low of $12.74 and a 12 month high of $40.56. The stock’s 50 day moving average price is $40.14 and its 200 day moving average price is $33.76.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). Equities research analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.